Indication
Shock
23 clinical trials
35 products
1 drug
Clinical trial
Efficacy, Safety and Tolerability of Nangibotide in Patients With Septic Shock. A Randomized, Double-blind, Placebo Controlled Dose Selection StudyStatus: Active (not recruiting), Estimated PCD: 2022-05-09
Product
NangibotideProduct
placeboClinical trial
Early Intravenous Hydrocortisone in Sepsis: a Randomized Control TrialStatus: Not yet recruiting, Estimated PCD: 2025-03-01
Product
Early hydrocortisoneProduct
Normal salineProduct
HydrocortisoneClinical trial
Midodrine for the Early Liberation of Vasopressor Support in the ICU - The LIBERATE Pilot StudyStatus: Completed, Estimated PCD: 2022-07-31
Product
MidodrineProduct
PlaceboClinical trial
Intravenous Methylene Blue for Treating Fluid-refractory, Catecholamine-resistant, Neonatal Septic Shock: a Randomized, Placebo-controlled, Superiority TrialStatus: Not yet recruiting, Estimated PCD: 2026-03-14
Product
Methylene BlueClinical trial
Australasian Resuscitation In Sepsis Evaluation: FLUid or Vasopressors In Emergency Department SepsisStatus: Recruiting, Estimated PCD: 2024-12-31
Product
VasopressorClinical trial
Sevoflurane Sedation: A Potentially Promising Immunomodulation in Patients With Septic ShockStatus: Not yet recruiting, Estimated PCD: 2025-02-01
Product
SevofluraneProduct
Control GroupClinical trial
Trauma Resuscitation With Low-Titer Group O Whole Blood or ProductsStatus: Recruiting, Estimated PCD: 2026-12-31
Product
LTOWBProduct
ComponentsClinical trial
Methylene Blue for the Prevention of Hypotension During Hemodialysis: a Randomized Open Label TrialStatus: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
Intravenous Epinephrine Bolus for Prevention of Postintubation Collapse in Intensive Care Septic Patients Predicted by Shock Index.Status: Recruiting, Estimated PCD: 2023-12-01
Clinical trial
Early Initiated Vasopressor Therapy vs. Standard Care of Primarily Fluid Therapy in Hypotensive Patients in the Emergency Department - A Pragmatic, Multi-center, Superiority, Randomized Controlled TrialStatus: Recruiting, Estimated PCD: 2025-12-31
Product
NoradrenalineClinical trial
Efficacy of a Glucagon-like-peptide-1 Agonist and Restrictive vs. Liberal Oxygen Supply in Patients Undergoing Coronary Artery Bypass Grafting or Aortic Valve Replacement - a 2-by-2 Factorial Designed, Randomized Clinical StudyStatus: Active (not recruiting), Estimated PCD: 2024-01-01
Product
ByettaProduct
ConoxiaProduct
Human AlbuminClinical trial
Empiric Calcium Versus Lab Based Treatment in Massive Transfusion Trauma Patients: A Feasibility Randomized Controlled TrialStatus: Not yet recruiting, Estimated PCD: 2025-12-01
Product
Calcium GluconateClinical trial
CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic ShockStatus: Recruiting, Estimated PCD: 2025-01-01
Product
DobutamineProduct
MilrinoneProduct
epinephrineProduct
Isotonic FluidDrug
VarlilumabClinical trial
A Randomized Double Blind Trial of Vasoactive Drugs for the Management of Shock in the ICUStatus: Recruiting, Estimated PCD: 2024-12-01
Product
NorepinephrineProduct
EpinephrineProduct
PhenylephrineProduct
VasopressinClinical trial
Norepinephrine Weaning Guided by the Hypotension Prediction Index in Vasoplegic Shock After Cardiac SurgeryStatus: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
Umbilical Mesenchymal Stromal Cells as Cellular Immunotherapy for Septic Shock: A Multi-Center, Double Blind, Phase II Randomized Controlled TrialStatus: Recruiting, Estimated PCD: 2026-09-30
Clinical trial
Prospective Multicentre Observational Study of Patients Treated With Vasopressin in Critical Care UnitsStatus: Not yet recruiting, Estimated PCD: 2026-06-01
Clinical trial
Impact of Endothelial and Leukocyte Senescence in Circulatory Shock StatesStatus: Recruiting, Estimated PCD: 2025-02-01
Clinical trial
L-carnitine as an Adjunct Treatment for Septic Shock Patients With Acute Kidney Injury: a Multicentre, Randomized, 2-parallel Group, Superiority TrialStatus: Recruiting, Estimated PCD: 2025-05-06
Product
L-CarnitineClinical trial
Beyond the Syndromic Approach in Critical Care: Identifying Biomarker-driven Subphenotypes of Circulatory ShockStatus: Active (not recruiting), Estimated PCD: 2025-07-01
Product
InotropeProduct
anti-bodiesClinical trial
A Randomized, Double Blind, Placebo-Controlled Trial to Investigate the Effect of Vitamin C, Hydrocortisone and Thiamine on the Outcome of Patients With Septic ShockStatus: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
An Open-label, Single-arm, Single-center Study Evaluating the Hemodynamic Response to Angiotensin-II When Used as the Second Vasopressor Agent for Septic ShockStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
SODium BICarbonate for Metabolic Acidosis in the Intensive Care Unit (SODa-BIC): A Multicentre, Randomised, Double-blind Clinical TrialStatus: Recruiting, Estimated PCD: 2026-07-01
Product
Sodium bicarbonateProduct
Dextrose